BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27023215)

  • 1. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Tsuji A; Yamamura K; Kitano Y; Inoue R; Kaida T; Higashi T; Taki K; Imai K; Komohara Y; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2016 Oct; 21(5):940-945. PubMed ID: 27023215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
    Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative platelet-to-lymphocyte ratio improves the performance of the international consensus guidelines in predicting malignant pancreatic cystic neoplasms.
    Goh BK; Teo JY; Allen JC; Tan DM; Chan CY; Lee SY; Tai DW; Thng CH; Cheow PC; Chow PK; Ooi LL; Chung AY
    Pancreatology; 2016; 16(5):888-92. PubMed ID: 27421563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Kuroki H; Taki K; Kaida T; Higashi T; Nitta H; Komohara Y; Beppu T; Takeya M; Baba H
    J Gastrointest Surg; 2015 Dec; 19(12):2171-7. PubMed ID: 26443528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
    Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
    Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 10. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data.
    Singhi AD; Zeh HJ; Brand RE; Nikiforova MN; Chennat JS; Fasanella KE; Khalid A; Papachristou GI; Slivka A; Hogg M; Lee KK; Tsung A; Zureikat AH; McGrath K
    Gastrointest Endosc; 2016 Jun; 83(6):1107-1117.e2. PubMed ID: 26709110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
    Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.
    Fritz S; Hackert T; Hinz U; Hartwig W; Büchler MW; Werner J
    Br J Surg; 2011 Jan; 98(1):104-10. PubMed ID: 20949535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma.
    Abe T; Nakata K; Kibe S; Mori Y; Miyasaka Y; Ohuchida K; Ohtsuka T; Oda Y; Nakamura M
    Ann Surg Oncol; 2018 Dec; 25(13):3996-4003. PubMed ID: 30225838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic Impact of Neutrophil-to-Lymphocyte Ratio for Intraductal Papillary Mucinous Neoplasms of the Pancreas With High-Grade Dysplasia and Associated Invasive Carcinoma.
    Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Takadate T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Furukawa T; Naitoh T; Unno M
    Pancreas; 2019 Jan; 48(1):99-106. PubMed ID: 30540681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
    Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
    Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis.
    Muraki T; Jang KT; Reid MD; Pehlivanoglu B; Memis B; Basturk O; Mittal P; Kooby D; Maithel SK; Sarmiento JM; Christians K; Tsai S; Evans D; Adsay V
    Mod Pathol; 2022 Jan; 35(1):96-105. PubMed ID: 34518632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer.
    Kim WJ; Lim TW; Park PJ; Choi SB; Kim WB
    ANZ J Surg; 2019 Jul; 89(7-8):E302-E307. PubMed ID: 30895709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.